Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced a key executive and board change via this Form 8-K filing. Effective March 2, 2017, the company appointed Christopher Fenimore as Vice President, Controller, succeeding Douglas S. McCorkle who is retiring on February 10, 2017. Mr. Fenimore will also assume the role of principal accounting officer upon his appointment, ensuring a smooth transition for financial reporting oversight. The company also elected N. Anthony Coles, M.D. as a Class II director to its Board of Directors on January 27, 2017, and he will serve on the Audit Committee. Dr. Coles' appointment aligns with the existing investor agreement with Sanofi, indicating a continued strategic relationship. These changes are important for investors to note as they pertain to the company's leadership and financial governance.
Key Highlights
- 1Appointment of Christopher Fenimore as Vice President, Controller, effective March 2, 2017.
- 2Retirement of current controller, Douglas S. McCorkle, effective February 10, 2017.
- 3Christopher Fenimore will also serve as the company's principal accounting officer.
- 4Election of N. Anthony Coles, M.D. as a Class II director to the Board of Directors, effective January 27, 2017.
- 5Dr. N. Anthony Coles appointed to serve on the Audit Committee of the Board.
- 6Dr. Coles' appointment is a replacement designee under the investor agreement with Sanofi.
- 7Dr. Coles will receive standard compensation for non-employee directors, including stock options.